Archive
All news, publications, and updates from Seek Labs.
BIO 2026: Where Pharma leaders Say AI Hasn’t Delivered AI hasn’t always been what it was cracked up to be in pharma. Here’s where execs say the technology hasn’t lived up to the hype. SAN DIEGO — AI adoption is still ticking up in pharma with 34% of companies leveraging the tech for specific functions,…
Panel Discusses Future of US Public Health System After Major Federal Layoffs The future of the U.S. public health system was debated by experts on June 23 during a panel at the BIO International Convention in San Diego, as recent government restructuring and staff cuts have left agencies like the Centers for Disease Control and…
Can the US public health system be rebuilt? Former FDA, CDC & NIH leaders discuss dismantling of HHS & the path to rebuilding public health.
Seek Labs Awarded U.S. Patent for Isothermal Molecular Amplification Chemistry Designed for Decentralized Testing Newly issued patent covers foundational amplification chemistry designed to support sensitive molecular detection without thermal cycling or centralized laboratory infrastructure May 7, 2026 SALT LAKE CITY, UT (Business Wire) — Seek Labs, a private TechBio company building programmable platforms to decode,…
Dr. Alison O’Mahony Named 2026 Mentor of the Year by BioHive April 28, 2026 Dr. Alison O’Mahony, Senior Vice President of Research and Development at Seek Labs, has been named Mentor of the Year as part of BioHive’s 2026 Best of BioHive Awards. The award recognizes individuals who have made exceptional contributions to mentorship and…
Jared Bauer Named Salt Lake City Titan 100 2026 Honoree April 20, 2026 Jared Bauer, co-founder and CEO of Seek Labs, has been named a 2026 Salt Lake City Titan 100 honoree. The Titan 100 program recognizes the region’s top 100 CEOs and C-level executives, selected for their exceptional leadership, vision, and impact across industries.…
Seek Labs Joins BioMaP-Consortium to Support U.S. Biomanufacturing Preparedness Efforts As a member of the BioMaP-Consortium, Seek Labs gains access to a collaborative network advancing next-generation biomanufacturing and healthcare innovation. March 19, 2026 Seek Labs today announced that it has joined the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), a national public-private partnership focused on strengthening the…
For Continuously Evolving Threats like Avian Influenza, We Must Design Durable Anti-Viral Therapeutics Highly pathogenic avian influenza (HPAI) illustrates a clear and urgent application for Seek Labs’ platform based programmable therapeutic. By Dr. Douglas Gladue | March 11, 2026 Highly pathogenic avian influenza (HPAI) is a persistent and economically disruptive disease threat. It has been…
Seek Labs Awarded $2 Million Federal Grant for a Novel CRISPR-Based, Mutation-Resistant Therapeutic to Combat Avian Flu in Partnership with Canadian Food Inspection Agency USDA grant is part of a broader federal push to find innovative solutions to fight the highly infectious avian flu (HPAI), which continues to spread globally and impact egg and poultry…
Stay connected
Stay connected to company milestones, scientific insights, and the work unfolding across BioSeeker, SAT, and Seek Diagnostics.